Medicus Pharma SkinJect Phase 2 Shows 73% Clearance, 75% Surgery Avoidance
Medicus Pharma’s Phase 2 SkinJect trial for basal cell carcinoma achieved 73% clinical or visual clearance at day 57 in the 200µg cohort. The microneedle-delivered doxorubicin therapy suggests 75% of patients could avoid Mohs surgery, underpinning an end-of-Phase 2 FDA meeting and partner talks.
1. Phase 2 SkinJect Efficacy
Medicus Pharma enrolled patients in a double-blind, placebo-controlled Phase 2 trial of SkinJect, a microneedle-based doxorubicin therapy targeting basal cell carcinoma. In the 200µg cohort, 73% of patients demonstrated clinical or visual tumor clearance at day 57 following excisional biopsy.
2. Potential to Reduce Surgical Intervention
CEO Raza Bokhari highlighted that three out of four treated patients are very likely to avoid Mohs micrographic surgery, addressing a backlog of roughly one million unmet procedures in the U.S. This non-invasive approach could shift treatment paradigms and reduce reliance on specialized surgical resources.
3. Regulatory Path and Partnership Outlook
The robust Phase 2 dataset positions Medicus Pharma for an end-of-Phase 2 meeting with the FDA to finalize pivotal study design. Positive efficacy signals and patented microneedle technology with active tip-loading aim to accelerate partnering discussions for commercialization.